Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | Consolidation therapy and updated results from the EMN02 trial

Pieter Sonneveld • 13 May 2022
COMy 2022
Multiple Myeloma
EMN02

In this video, Pieter Sonneveld, MD, PhD, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands, shares some updates from the EMN02 trial (NCT01208766), highlighting the importance of consolidation therapy in patients with newly diagnosed multiple myeloma, and the need to make consolidation therapy a standard part of clinical practice. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

More from Pieter Sonneveld

2:54
The PERSEUS trial: primary results of D-VRd vs VRd in newly diagnosed, transplant eligible MM
Pieter Sonneveld • 11 Dec 2023
Reaching a cure for multiple myeloma
Gareth Morgan et al. • 15 Apr 2023
1:57
The benefit of double autologous transplantation in multiple myeloma patient subgroups
Pieter Sonneveld • 24 Oct 2022
1:27
Do CAR-T therapies play a role in earlier lines of therapy in multiple myeloma?
Pieter Sonneveld • 24 Oct 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals